Duration of Untreated Psychosis and Duration of Untreated Illness: New Vistas
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The duration of untreated illness (DUI), defined as the interval between the onset of a psychiatric disorder and the administration of the first pharmacological treatment, has been increasingly investigated in the last decade as a predictor of outcome across different psychiatric conditions including schizophrenia and psychotic disorders (duration of untreated psychosis), and mood and anxiety disorders. Converging evidence indicates that a prolonged DUI may be viewed as a negative prognostic factor in schizophrenia and increasing data point toward a similar conclusion in mood and anxiety disorders. Through a Medline search, the present article highlights the role of the DUI in this group of psychiatric disorders, focusing on social and psychopathological determinants of the DUI, as well as the clinical consequences related to a longer DUI in terms of outcome. Hypotheses on neurobiological mechanisms underpinning outcome differences in relation to a prolonged DUI are provided and methodological limitations related to the assessment of the DUI in published studies and clinical practice discussed. Finally, given that DUI is supposed to be a potentially modifiable prognostic factor, intervention programs aimed to reduce this variable are briefly considered and discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 1×
“For the latter, NMDA receptor hypofunction would result in reduced activation of GABAergic inhibitory neurons, leading to an excitotoxic state.(31) Alternatively, prolonged stress, including stress resulting from untreated psychosis, may activate the hypothalamic-pituitary-adrenal (HPA) axis, leading to greater glucoc…”
Hippocampal Volume Reduction in Major Depression
Bremner, J. D., Narayan, M., Anderson, E. R., Staib, L. H., Miller, H. L., & Charney, D. S. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.115 · Cited by 1,670
Hippocampal volume and depression: a meta-analysis of MRI studies
Videbech, P., & Ravnkilde, B. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.1957 · Cited by 1,590
Glial reduction in the subgenual prefrontal cortex in mood disorders
Öngür, D., Drevets, W. C., & Price, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13290 · Cited by 1,525
Sheline, Y. I., Sanghavi, M., Mintun, M. A., & Gado, M. H. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05034.1999 · Cited by 1,382
Untreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180
Depression: Perspectives from Affective Neuroscience
Davidson, R. J., Pizzagalli, D., Nitschke, J. B., & Putnam, K. (2002) · Annual Review of Psychology · doi:10.1146/annurev.psych.53.100901.135148 · Cited by 1,138
Adult brain neurogenesis and psychiatry: a novel theory of depression
Jacobs, B. L., van Praag, H., & Gage, F. H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000712 · Cited by 964
Koolschijn, P. C. M. P., van Haren, N. E. M., Lensvelt‐Mulders, G. J. L. M., Hulshoff Pol, H. E., & Kahn, R. S. (2009) · Human Brain Mapping · doi:10.1002/hbm.20801 · Cited by 902
Malberg, J. E., & Duman, R. S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300234 · Cited by 815
Cotter, D., Mackay, D., Landau, S., Kerwin, R., & Everall, I. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.6.545 · Cited by 766
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568
Stice, E., Shaw, H., Bohon, C., Marti, C. N., & Rohde, P. (2009) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0015168 · Cited by 553
Regulation of adult neurogenesis by antidepressant treatment
Duman, R. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00358-x · Cited by 463
Preventing the Onset of Depressive Disorders: A Meta-Analytic Review of Psychological Interventions
Cuijpers, P., van Straten, A., Smit, F., Mihalopoulos, C., & Beekman, A. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07091422 · Cited by 456
Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes
Hamidi, M., Drevets, W. C., & Price, J. L. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.11.006 · Cited by 369
Hulshoff Pol, H. E., & Kahn, R. S. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm168 · Cited by 364
Merry, S. N., McDowell, H. H., Hetrick, S. E., Bir, J. J., & Muller, N. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003380.pub2 · Cited by 284
Roberts, N. P., Kitchiner, N. J., Kenardy, J., & Bisson, J. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08040590 · Cited by 242
Roberts, N. P., Kitchiner, N. J., Kenardy, J., & Bisson, J. I. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006869.pub2 · Cited by 218
Predictors of efficacy in depression prevention programmes: Meta-analysis
Jané-Llopis, E., Hosman, C., Jenkins, R., & Anderson, P. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.183.5.384 · Cited by 210 · cited 1×
“In particular, prevention programs subdivided into universal, selective, and indicated prevention according to the presence of risk factors/soft symptoms, and represented by educational and psychological treatments, have been reviewed and were the object of meta-analyses with small but significant effect-sizes, partic…”
Grunze, H., Kasper, S., Goodwin, G., Bowden, C., Baldwin, D., Licht, R., Vieta, E., Möller, H.-J., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150612 · Cited by 185 · cited 1×
“These currently include not only lithium and anticonvulsants but also atypical antipsychotics, and are considered the gold standard in the pharmacological treatment of bipolar disorder by major international treatment guidelines.(41)-(42) Nevertheless, bipolar disorder may frequently have a depressive onset and most p…”
Can We Predict the Persistence of Depression?
Scott, J., Eccleston, D., & Boys, R. (1992) · British Journal of Psychiatry · doi:10.1192/bjp.161.5.633 · Cited by 131
Prevention of anxiety disorders
Bienvenu, O. J., & Ginsburg, G. S. (2007) · International Review of Psychiatry · doi:10.1080/09540260701797837 · Cited by 93
Adequacy of treatment received by diagnosed and undiagnosed patients with bipolar I and II disorders
Arvilommi, P., Suominen, K. S., Mantere, O. K., Leppämäki, S., Valtonen, H., & Isometsä, E. T. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0114 · Cited by 43
Roberts, N. P., Kitchiner, N. J., Kenardy, J., & Bisson, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007944 · Cited by 34
Cited by
Duration of untreated bipolar disorder: missed opportunities on the long road to optimal treatment
Drancourt, N., Etain, B., Lajnef, M., Henry, C., Raust, A., Cochet, B., Mathieu, F., Gard, S., MBailara, K., Zanouy, L., et al. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01917.x · Cited by 292
Early intervention for obsessive compulsive disorder: An expert consensus statement
Fineberg, N. A., Dell'Osso, B., Albert, U., Maina, G., Geller, D., Carmi, L., Sireau, N., Walitza, S., Grassi, G., Pallanti, S., et al. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.02.002 · Cited by 158
Self-citationDuration of untreated illness as a key to early intervention in schizophrenia: a review.
Murru, A., & Carpiniello, B. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2016.10.003 · Cited by 135
“From an epidemiologic perspective, large sample studies in SCZ found mean values of DUP ranging from 8 to 48 weeks, whereas higher DUI values, comprised between 3 and 8 years, on average, were reported for mood disorders and anxiety disorders [9], [13]–[17] Although the applicability of DUI may vary according to diffe…”
BackgroundDell’Osso, B., Glick, I. D., Baldwin, D. S., & Altamura, A. C. (2013) · Psychopathology · doi:10.1159/000338608 · Cited by 118
Self-citationIyer, S. N., Shah, J., Boksa, P., Lal, S., Joober, R., Andersson, N., Fuhrer, R., Abdel-Baki, A., Beaton, A. M., Reaume-Zimmer, P., et al. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2232-2 · Cited by 44
Metadata
- Authors
- Dell'Osso, B., & Altamura, A. C.
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2010-04
- Volume
- 15
- Issue
- 4
- Pages
- 238-246
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- OpenAlex
- W167750310
- Cited by
- 70
- References
- 27
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.